Nuclear matrix protein 22 (NMP22) is a FDA approved
biomarker for bladder cancer. The objective of this study is to develop
a simple NMP22 immumosensor (NMP22-IMS) for accurate
measurement of NMP22. The NMP22-IMS was constructed with
NMP22 antibody immobilized on screen-printed carbon electrodes.
The construction procedures and antibody immobilization are simple.
Results showed that the NMP22-IMS has an excellent (r2³0.95)
response range (20 – 100 ng/mL). In conclusion, a simple and reliable
NMP22-IMS was developed, capable of precisely determining urine
 Department of Health, Executive Yuan, R.O.C. (TAIWAN), "Health
Statistics in Taiwan, 2009," 2009. Last accessed: 23rd March 2012.
 GLOBOCAN 2008´╝êIARC´╝ë Section of Cancer Information, "WORLD -
Most frequent cancers: both sexes," 2008. Last accessed: 23rd March
2012. Available at:
 N. Gan, L.Y. Wang, W.M. Xu, T.H. Li, Q.L. Jiang, "Electrochemical
Immuno-Biosensor for the Rapid Determination of Nuclear Matrix
Protein 22 (NMP22) antigen in Urine Samples by Co(III)
Phthlocyanine/Fe3O4/Au Collide Coimmobilized Electrode," Chin J
Anal Chem, vol. 35, pp. 1553-1558, November 2007.